People · Operator
Named in public records as an officer, director or promoter · active 2003–2017 · Biotechnology, Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Centrexion Therapeutics Corp | — | Biotechnology | Series C | $202.0M | $35.2M | 2017 |
| PMV Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $73.7M | $2.6B | 2017 |
| Integrated Diagnostics, Inc. | — | Biotechnology | Series B | $45.3M | $242.1M | 2014 |
| Applied Genetic Technologies Corp | — | Biotechnology | Series B | $42.9M | $340.5M | 2003 |
| Potenza Therapeutics, Inc. | — | Pharmaceuticals | Series B | $35.0M | $170.0M | 2014 |
| Drais Pharmaceuticals Inc | — | Biotechnology | Series B | $20.0M | $793.8M | 2007 |
| Macrogenics Inc | — | Biotechnology | Series A | $12.0M | $434.4M | 2011 |
| Vesuvius Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $10.2M | $316.7M | 2014 |
| Arcion Therapeutics, Inc. | — | Biotechnology | Series A | $8.2M | $54.2M | 2010 |
| USDS, Inc. | — | Other Health Care | Series A | $6.1M | $92.4M | 2010 |
Arnold Oronsky at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Arnold Oronsky on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Luke Evnin | 2 | 12 |
| Stephen Davis | 2 | 8 |
| David Cordo | 2 | 6 |
| Daniel Hicklin | 2 | 4 |
| Phil Gutry | 2 | 4 |
| SCOTT KOENIG | 2 | 2 |
| Peter Thompson | 1 | 16 |
| Garheng Kong | 1 | 16 |
| Isaac Blech | 1 | 14 |
| Michael Liang | 1 | 9 |
| Ed Hurwitz | 1 | 9 |
| David Collier | 1 | 8 |
| David Barker | 1 | 7 |
| JEFF BIRD | 1 | 7 |
| PAUL SEKHRI | 1 | 7 |
| Sol Barer | 1 | 6 |
| Sol J. Barer | 1 | 6 |
| Arnold L. Oronsky | 1 | 6 |
| Sakae Asanuma | 1 | 6 |
| James Campbell | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.